CONTACT: Michael D. Witzeman (513) 762- 6714 Chemed Reports Third-Quarter 2026
CONTACT: Michael D. Witzeman (513) 762- 6714 Chemed Reports Third-Quarter 2026 Results CINCINNATI, October 27, 2026— Chemed Corporation (Chemed) (NYSE: CHE ), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter , the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its third quarter ended September 30, 2026, versus the comparable prior-year period. Results for Quarter Ended September 30, 2026 Consolidated operating results:
· Net Income, excluding certain discrete items, of $70.8 million, an increase of 44.7%
· Adjusted EBITDA, excluding Medicare Cap, of $92.5 million, an increase of 31.4%
· Adjusted EBITDA margin, excluding Medicare Cap, of 20.2%, an increase of 318-basis points
· Net Income, excluding certain discrete items, of $33.3 million, a decline of 1.8%
VITAS VITAS net revenue was $457.4 million in the third quarter of 2026, which is an increase of 12.2% when compared to the prior-year period. This revenue increase is comprised primarily of a 9.4% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.2%. Acuity mix shift negatively impacted revenue growth 25-basis points in the quarter when compared to the prior-year period’s revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes positively impacted revenue growth by 85-basis points. Total VITAS admissions increased 7.2% in the third quarter of 2026 compared to the third quarter of 2025. In the third quarter of 2026, VITAS accrued $828,000 in Medicare Cap billing limitation. This compares to the Medicare Cap billing limitation recorded in the third quarter of 2025 of $6.1 million. No Medicare Cap billing limitation was recorded in the third quarter of 2026 for the Florida combined program, and none is anticipated for the 2026 fiscal period. Of VITAS’ 33 Medicare provider numbers, 21 provider numbers have an anticipated full-year Medicare Cap cushion of 10% or greater, seven provider numbers have a cushion between 0% and 10%, and five provider numbers have a Medicare Cap billing limitation totaling $6.1 million. Average revenue per patient per day in the third quarter of 2026 was $209.11 which is 196-basis points above the prior-year period. Reimbursement for routine home care and high-acuity care averaged $187.69 and $1,147.26, respectively. During the quarter, high-acuity days-of- care were 2.2% of total days of care, a decline of 5-basis points when compared to the prior-year quarter. The third quarter 2026 gross margin, excluding Medicare Cap, was 25.4%, a 221-basis point increase from the same period of 2025. Selling, general and administrative expenses were $23.1 million in the third quarter of 2026 compared to $25.2 million in the prior-year quarter. Adjusted EBITDA, excluding Medicare Cap, totaled $92.5 million in the quarter, an increase of 31.4% when compared to the prior-year period. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 20.2%. Roto-Rooter Roto- Rooter generated quarterly revenue of $233.5 million in the third quarter of 2026, an increase of 7.5%, when compared to the prior-year quarter. Roto-Rooter branch commercial revenue in the quarter totaled $59.9 million, an increase of 9.0% from the prior-year period. This aggregate commercial revenue change consisted of plumbing increasing 10.6%, drain cleaning increasing 6.8%, excavation increasing 5.5% and water restoration increasing 30.7%. Roto-Rooter branch residential revenue in the quarter totaled $158.8 million, an increase of 5.2% over the prior-year period. This aggregate residential revenue change consisted of excavation increasing 7.8%, plumbing increasing 5.9%, water restoration increasing 6.2% and drain cleaning increasing 4.5%. In the third quarter of 2026, revenue from independent contractors was $16.9 million which is flat compared to the same period of 2025. Roto-Rooter’s third quarter 2026 gross margin was 50.3%. This compares to the prior-year quarter’s gross margin of 50.7%. Roto-Rooter’s selling, general and administrative expenses were $71.0 million in the quarter, which is an increase of 17.1% compared to the third quarter of 2025. Adjusted EBITDA in the third quarter of 2026 totaled $48.2 million, a decline of 2.5% when compared to the third quarter of 2025. Adjusted EBITDA margin in the quarter was 20.6% which represents a 213-basis point decline from the third quarter of 2025. During the third quarter of 2026, Roto- Rooter re-acquired multiple franchise territories in California for approximately $62.5 million. Collectively, these territories include a population of over 12 million people. Slightly over half of the revenue associated with acquired territories will become part of our owned and operated branch locations. Two new branches will be established in Sacramento and San Diego while other territories will be absorbed by existing branches. The remaining locations will become part of our independent contractor operating model. Chemed Consolidated As of September 30, 2026, Chemed had total cash and cash equivalents of $48.4 million and $236.0 million in long-term debt. In April 2026, Chemed entered into a new five-year $450 million Amended and Restated Credit Agreement (Credit Agreement). This Credit Agreement consists of a $450 million revolving line of credit and a $250 million expansion feature. The interest rate on this Credit Agreement has a floating rate that is currently SOFR plus 100-basis points. There is approximately $166.7 million undrawn borrowing capacity under the Credit Agreement after excluding $47.3 million for Letters of Credit. During the quarter, the Company repurchased 125,000 shares of Chemed stock for $66.0 million which equates to a cost per share of $528.24. Over the trailing 12-months, the Company has repurchased 1,235,000 shares of Chemed stock at an average price of $427.62 per share. As of September 30, 2026, there was approximately $73.7 million of remaining share repurchase authorization under the Company’s plan. Guidance Update Based on the Company’s financial results through September 30, 2026, we estimate that we will be at or slightly above the high-end of our full-year 2026 adjusted EPS guidance issued in conjunction with our press release, dated July 28, 2026, discussing our second quarter 2026 earnings. Further operational detail will be provided during the investor conference call. Conference Call As previously disclosed, Chemed will host a conference call and webcast at 10 a.m. ET, on Wednesday October 28, 2026, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media- server.com/mmc/p/v5gcs68f . Participants may also register via teleconference at: https://register-conf.media- server.com/register/BId8ccb8a390cc4b6fbb29ab2b99a55028 . Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time. A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed’s website. Chemed operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible. Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.
This press release contains information about Chemed’s EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s Net Income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed’s operations, including Medicare Cap and Medicare reimbursement rates, Chemed’s estimates of the effect of Medicare Cap on VITAS’ revenues and future prospects, Chemed’s expectations regarding VITAS’ patient mix and Chemed’s expectations regarding demand for Roto-Rooter’s services. Because forward- looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed’s control. Chemed’s actual results and financial condition may differ materially from those indicated in the forward- looking statements included in this press release, including as a result of the risks described above and those described in Chemed’s Annual Report on Form 10-K for the year ended December 31, 2025 and in its Quarterly Reports filed in 2026. Any forward-looking statement made by Chemed in this press release is based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATED BALANCE SHEETS (in thousands, except per share data)(unaudited) Assets September 30, Current assets 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents $ 48,427 $ 129,752 Accounts receivable less 254,861 215,570 allowances Inventories 7,748 8,238 Prepaid income taxes 16,346 7,106 Prepaid expenses 38,346 34,577 Total current assets 365,728 395,243 Investments of deferred compensation 144,845 136,021 plans held in trust Properties and equipment, at cost less 216,961 203,939 accumulated depreciation Lease right of use asset 144,029 128,362 Identifiable intangible assets less 78,791 84,930 accumulated amortization Goodwill 754,758 666,987 Other assets 13,327 8,137 Total Assets $ 1,718,439 $ 1,623,619 Liabilities Current liabilities Accounts payable $ 65,297 $ 48,095 Accrued insurance 77,044 65,733 Accrued income taxes - 1,469 Accrued compensation 89,044 79,668 Short-term lease liability 41,209 42,013 Other current liabilities 58,340 55,063 Total current liabilities 330,934 292,041 Deferred income taxes 18,855 9,687 Deferred compensation 142,421 132,380 liabilities Long-term debt 236,000 - Long-term lease liability 114,985 99,461 Other liabilities 13,823 13,367 Total Liabilities 857,018 546,936 Stockholders' Equity Capital stock 37,762 37,593 Paid-in capital 1,693,508 1,581,067 Retained earnings 3,135,794 2,887,123 Treasury stock, at cost -4,008,128 -3,431,475 Deferred compensation payable in Company 2,485 2,375 stock Total Stockholders' Equity 861,421 1,076,683 Total Liabilities and Stockholders' $ 1,718,439 $ 1,623,619 Equity
CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)(unaudited) For the Nine Months Cash Flows from Ended September 30, Operating Activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 205,653 $ 188,487 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 51,260 48,511 amortization Stock option expense 24,285 24,374 Noncash long-term 6,784 3,057 incentive compensation Legal settlements 6,000 1,850 Noncash directors' 1,191 1,123 compensation Benefit for deferred -456 -16,259 income taxes Amortization of debt 255 241 issuance costs Changes in operating assets and liabilities, excluding amounts acquired in business combinations: Increase in accounts -71,304 -44,403 receivable Increase in -205 -45 inventories Increase in prepaid -11,528 -8,603 expenses Increase in accounts payable and other current 27,783 10,102 liabilities Change in current -7,685 -2,162 income taxes Net change in lease assets and -667 -576 liabilities (Increase)/decrease in -9,356 42,048 other assets Increase in other 6,772 6,355 liabilities Other sources 840 639 Net cash provided by operating 229,622 254,739 activities Cash Flows from Investing Activities Business combinations, net of cash -96,050 -225 acquired Capital expenditures -51,355 -46,447 Proceeds from sale of 488 3,751 fixed assets Other uses -502 -468 Net cash used by -147,419 -43,389 investing activities Cash Flows from Financing Activities Proceeds from revolving line of 843,280 - credit Payments on revolving -607,280 - line of credit Purchases of treasury -350,042 -256,944 stock Proceeds from exercise 30,281 27,152 of stock options Dividends paid -25,234 -23,196 Change in cash 6,818 610 overdrafts payable Capital stock surrendered to pay taxes -3,832 -8,484 on stock-based compensation Debt issuance costs -1,349 - Other (uses)/sources -933 914 Net cash used by -108,291 -259,948 financing activities Decrease in Cash and -26,088 -48,598 Cash Equivalents Cash and cash equivalents at 74,515 178,350 beginning of year Cash and cash equivalents at end of $ 48,427 $ 129,752 period
VITAS has 14 large (greater than 450 ADC), 25 medium (greater than 200 but less than 450 ADC) and 21 small (less than 200 ADC) hospice (c) programs. Of Vitas' 33 Medicare provider numbers, for the current cap year, 21 provider numbers have a Medicare cap cushion of greater than 10%, seven provider numbers have a Medicare cap cushion between 0% and 10%, and five provider numbers have a Medicare cap liability.
Full text with the tables
CONTACT: Michael D. Witzeman (513) 762- 6714 Chemed Reports Third-Quarter 2026
Results CINCINNATI, October 27, 2026— Chemed Corporation (Chemed) (NYSE: CHE ),
which operates VITAS Healthcare Corporation (VITAS), the nation’s largest
providers of end-of-life care, and Roto-Rooter , the nation’s largest commercial
and residential plumbing and drain cleaning services provider, reported
financial results for its third quarter ended September 30, 2026, versus the
comparable prior-year period. Results for Quarter Ended September 30, 2026
Consolidated operating results:
· Revenue increased 10.6% to $690.9 million
· GAAP Diluted Earnings-per-Share (EPS) of $5.45, an increase of 22.2%
· Adjusted Diluted EPS of $6.75, an increase of 28.1%
VITAS segment operating results:
· Net Patient Revenue of $457.4 million, an increase of 12.2%
· Average Daily Census (ADC) of 24,428, an increase of 9.4%
· Admissions of 18,995, an increase of 7.2%
· Net Income, excluding certain discrete items, of $70.8 million, an
increase of 44.7%
· Adjusted EBITDA, excluding Medicare Cap, of $92.5 million, an increase
of 31.4%
· Adjusted EBITDA margin, excluding Medicare Cap, of 20.2%, an increase
of 318-basis points
Roto-Rooter segment operating results:
· Revenue of $233.5 million, an increase of 7.5%
· Net Income, excluding certain discrete items, of $33.3 million, a
decline of 1.8%
· Adjusted EBITDA of $48.2 million, a decline of 2.5%
· Adjusted EBITDA margin of 20.6%, a decline of 213-basis points
VITAS VITAS net revenue was $457.4 million in the third quarter of 2026, which
is an increase of 12.2% when compared to the prior-year period. This revenue
increase is comprised primarily of a 9.4% increase in days-of-care and a
geographically weighted average Medicare reimbursement rate increase of
approximately 2.2%. Acuity mix shift negatively impacted revenue growth 25-basis
points in the quarter when compared to the prior-year period’s revenue and
level-of-care mix. The combination of Medicare Cap and other contra revenue
changes positively impacted revenue growth by 85-basis points. Total VITAS
admissions increased 7.2% in the third quarter of 2026 compared to the third
quarter of 2025. In the third quarter of 2026, VITAS accrued $828,000 in
Medicare Cap billing limitation. This compares to the Medicare Cap billing
limitation recorded in the third quarter of 2025 of $6.1 million. No Medicare
Cap billing limitation was recorded in the third quarter of 2026 for the Florida
combined program, and none is anticipated for the 2026 fiscal period. Of VITAS’
33 Medicare provider numbers, 21 provider numbers have an anticipated full-year
Medicare Cap cushion of 10% or greater, seven provider numbers have a cushion
between 0% and 10%, and five provider numbers have a Medicare Cap billing
limitation totaling $6.1 million. Average revenue per patient per day in the
third quarter of 2026 was $209.11 which is 196-basis points above the prior-year
period. Reimbursement for routine home care and high-acuity care averaged
$187.69 and $1,147.26, respectively. During the quarter, high-acuity days-of-
care were 2.2% of total days of care, a decline of 5-basis points when compared
to the prior-year quarter. The third quarter 2026 gross margin, excluding
Medicare Cap, was 25.4%, a 221-basis point increase from the same period of
2025. Selling, general and administrative expenses were $23.1 million in the
third quarter of 2026 compared to $25.2 million in the prior-year quarter.
Adjusted EBITDA, excluding Medicare Cap, totaled $92.5 million in the quarter,
an increase of 31.4% when compared to the prior-year period. Adjusted EBITDA
margin in the quarter, excluding Medicare Cap, was 20.2%. Roto-Rooter Roto-
Rooter generated quarterly revenue of $233.5 million in the third quarter of
2026, an increase of 7.5%, when compared to the prior-year quarter. Roto-Rooter
branch commercial revenue in the quarter totaled $59.9 million, an increase of
9.0% from the prior-year period. This aggregate commercial revenue change
consisted of plumbing increasing 10.6%, drain cleaning increasing 6.8%,
excavation increasing 5.5% and water restoration increasing 30.7%. Roto-Rooter
branch residential revenue in the quarter totaled $158.8 million, an increase of
5.2% over the prior-year period. This aggregate residential revenue change
consisted of excavation increasing 7.8%, plumbing increasing 5.9%, water
restoration increasing 6.2% and drain cleaning increasing 4.5%. In the third
quarter of 2026, revenue from independent contractors was $16.9 million which is
flat compared to the same period of 2025. Roto-Rooter’s third quarter 2026 gross
margin was 50.3%. This compares to the prior-year quarter’s gross margin of
50.7%. Roto-Rooter’s selling, general and administrative expenses were $71.0
million in the quarter, which is an increase of 17.1% compared to the third
quarter of 2025. Adjusted EBITDA in the third quarter of 2026 totaled $48.2
million, a decline of 2.5% when compared to the third quarter of 2025. Adjusted
EBITDA margin in the quarter was 20.6% which represents a 213-basis point
decline from the third quarter of 2025. During the third quarter of 2026, Roto-
Rooter re-acquired multiple franchise territories in California for
approximately $62.5 million. Collectively, these territories include a
population of over 12 million people. Slightly over half of the revenue
associated with acquired territories will become part of our owned and operated
branch locations. Two new branches will be established in Sacramento and San
Diego while other territories will be absorbed by existing branches. The
remaining locations will become part of our independent contractor operating
model. Chemed Consolidated As of September 30, 2026, Chemed had total cash and
cash equivalents of $48.4 million and $236.0 million in long-term debt. In April
2026, Chemed entered into a new five-year $450 million Amended and Restated
Credit Agreement (Credit Agreement). This Credit Agreement consists of a $450
million revolving line of credit and a $250 million expansion feature. The
interest rate on this Credit Agreement has a floating rate that is currently
SOFR plus 100-basis points. There is approximately $166.7 million undrawn
borrowing capacity under the Credit Agreement after excluding $47.3 million for
Letters of Credit. During the quarter, the Company repurchased 125,000 shares of
Chemed stock for $66.0 million which equates to a cost per share of $528.24.
Over the trailing 12-months, the Company has repurchased 1,235,000 shares of
Chemed stock at an average price of $427.62 per share. As of September 30, 2026,
there was approximately $73.7 million of remaining share repurchase
authorization under the Company’s plan. Guidance Update Based on the Company’s
financial results through September 30, 2026, we estimate that we will be at or
slightly above the high-end of our full-year 2026 adjusted EPS guidance issued
in conjunction with our press release, dated July 28, 2026, discussing our
second quarter 2026 earnings. Further operational detail will be provided during
the investor conference call. Conference Call As previously disclosed, Chemed
will host a conference call and webcast at 10 a.m. ET, on Wednesday October 28,
2026, to discuss the company's quarterly results and to provide an update on its
business. Participants may access a live webcast of the conference call through
the investor relations section of Chemed’s website, Investor Relations Home |
Chemed Corporation or the hosting website https://edge.media-
server.com/mmc/p/v5gcs68f . Participants may also register via teleconference
at: https://register-conf.media-
server.com/register/BId8ccb8a390cc4b6fbb29ab2b99a55028 . Once registration is
completed, participants will be provided with a dial-in number containing a
personalized conference code to access the call. All participants are instructed
to dial-in 15 minutes prior to the start time. A taped replay of the conference
call will be available beginning approximately two hours after the call's
conclusion. You may access the replay via webcast through the investor relations
section of Chemed’s website. Chemed operates in the healthcare field through its
VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services
to patients with severe, life-limiting illnesses. This type of care is focused
on making the terminally ill patient's final days as comfortable and pain-free
as possible. Chemed operates in the residential and commercial plumbing and
drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides
plumbing, drain cleaning, and water cleanup services through company-owned
branches, independent contractors and franchisees in the United States and
Canada. Roto-Rooter also has licensed master franchisees in the republics of
Indonesia and Singapore, and the Philippines.
This press release contains information about Chemed’s EBITDA, Adjusted EBITDA,
and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP
and which exclude components that are important to understanding Chemed’s
financial performance. In reporting its operating results, Chemed provides
EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and
others evaluate the Company’s operating results, compare its operating
performance with that of similar companies that have different capital
structures and evaluate its ability to meet its future debt service, capital
expenditures and working capital requirements. Chemed’s management similarly
uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in
evaluating the performance of the Company across fiscal periods and in assessing
how its performance compares to its peer companies. These measures also help
Chemed’s management to estimate the resources required to meet Chemed’s future
financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and
Adjusted Diluted EPS should not be considered in isolation or as a substitute
for comparable measures calculated and presented in accordance with GAAP. We
calculated Adjusted EBITDA margin by dividing Adjusted EBITDA by service revenue
and sales. A reconciliation of Chemed’s Net Income to its EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS is presented in the tables following the text of
this press release. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION Statements
in this press release contain forward-looking statements within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements can be identified by words such as
“anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,”
“estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will”
and similar references to future periods and are based upon assumptions subject
to certain known and unknown risks, uncertainties, contingencies and other
factors, including, but not limited to, the impact of laws and regulations on
Chemed’s operations, including Medicare Cap and Medicare reimbursement rates,
Chemed’s estimates of the effect of Medicare Cap on VITAS’ revenues and future
prospects, Chemed’s expectations regarding VITAS’ patient mix and Chemed’s
expectations regarding demand for Roto-Rooter’s services. Because forward-
looking statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult to predict
and many of which are outside of Chemed’s control. Chemed’s actual results and
financial condition may differ materially from those indicated in the forward-
looking statements included in this press release, including as a result of the
risks described above and those described in Chemed’s Annual Report on Form 10-K
for the year ended December 31, 2025 and in its Quarterly Reports filed in 2026.
Any forward-looking statement made by Chemed in this press release is based only
on information currently available to Chemed and speaks only as of the date on
which it is made. Chemed undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or
otherwise.
CHEM…
CORP…
AND
SUBS…
COMP…
CONS…
STAT…
OF
INCO…
(in
thou…
exce…
per
share
data…
Serv…
reve…
and
sales
Cost
of
serv…
prov…
and
goods
sold
Sell…
gene…
and
admi…
expe…
(aa)
Depr…
Amor…
Other
oper…
expe…
Total
costs
and
expe…
Inco…
from
oper…
Inte…
expe…
Other
inco… 690,940 624,9… 2,021… 1,890,…
(bb) 457,978 425,1… 1,351… 1,289,…
Inco… 111,469 105,7… 340,9… 311,685
befo… 14,427 13,664 42,997 40,798
inco… 2,974 2,570 8,263 7,713
taxes 7,670 2,998 7,740 3,075
Inco… 594,518 550,1… 1,751… 1,653,…
taxes Three 96,422 74,750 Nine 270,2… 237,592
Net Months (2,097) (457) Months (4,39… (1,229)
inco… Ended 2,383 9,251 Ended 11,071 13,970
Earn… Septe… 96,708 83,544 Septem… 276,8… 250,333
Per 30, (25,06… (19,3… 30, (71,2… (61,84…
Share 2026 71,648 2025 64,237 2026 205,6… 2025 188,487
──────────────────────────────────────────────────────────────────────────────
Net $ 5.49 $ 4.46 $ 15.46 $ 12.97
inco…
Aver…
numb…
of 13,058 14,394 13,300 14,535
shar…
outs…
Dilu…
Earn…
Per
Share
Net $ 5.45 $ 4.46 $ 15.43 $ 12.89
inco…
Aver…
numb…
of 13,135 14,409 13,329 14,620
shar…
outs…
(aa)
Sell…
gene…
and
admi…
("SG…
expe…
comp…
(in
thou…
Three Nine
Months Months
Ended Ended
Septe… Septem…
30, 30,
2026 2025 2026 2025
SG&A
expe…
befo…
long…
ince…
comp…
and
the
impa…
of
mark…
value
adju…
rela…
to
defe…
comp… $ 106,241 $ 99,288 $ 324,4… $ 301,600
plans
Mark…
value
adju…
rela…
to
defe…
comp… 2,077 6,703 9,661 6,791
trus…
Long…
ince… 3,151 -216 6,904 3,294
comp…
Total
SG&A $ 111,469 $ 105,7… $ 340,9… $ 311,685
expe…
(bb)
Other
inco…
comp…
(in
thou…
Three Nine
Months Months
Ended Ended
Septe… Septem…
30, 30,
2026 2025 2026 2025
Mark…
value
adju…
rela…
to
defe…
comp… $ 2,077 $ 6,703 $ 9,661 $ 6,791
trus…
Inte… 295 2,555 1,399 7,186
inco…
Other 11 -7 11 -7
Total
other $ 2,383 $ 9,251 $ 11,071 $ 13,970
inco…
CHEMED CORPORATION AND
SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per
share data)(unaudited)
Assets September 30,
Current assets 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash equivalents $ 48,427 $ 129,752
Accounts receivable less 254,861 215,570
allowances
Inventories 7,748 8,238
Prepaid income taxes 16,346 7,106
Prepaid expenses 38,346 34,577
Total current assets 365,728 395,243
Investments of deferred
compensation 144,845 136,021
plans held in trust
Properties and equipment,
at cost less 216,961 203,939
accumulated depreciation
Lease right of use asset 144,029 128,362
Identifiable intangible
assets less 78,791 84,930
accumulated amortization
Goodwill 754,758 666,987
Other assets 13,327 8,137
Total Assets $ 1,718,439 $ 1,623,619
Liabilities
Current liabilities
Accounts payable $ 65,297 $ 48,095
Accrued insurance 77,044 65,733
Accrued income taxes - 1,469
Accrued compensation 89,044 79,668
Short-term lease liability 41,209 42,013
Other current liabilities 58,340 55,063
Total current liabilities 330,934 292,041
Deferred income taxes 18,855 9,687
Deferred compensation 142,421 132,380
liabilities
Long-term debt 236,000 -
Long-term lease liability 114,985 99,461
Other liabilities 13,823 13,367
Total Liabilities 857,018 546,936
Stockholders' Equity
Capital stock 37,762 37,593
Paid-in capital 1,693,508 1,581,067
Retained earnings 3,135,794 2,887,123
Treasury stock, at cost -4,008,128 -3,431,475
Deferred compensation
payable in Company 2,485 2,375
stock
Total Stockholders' Equity 861,421 1,076,683
Total Liabilities and
Stockholders' $ 1,718,439 $ 1,623,619
Equity
CHEMED CORPORATION AND
SUBSIDIARY COMPANIES
CONSOLIDATED
STATEMENTS OF CASH
FLOWS
(in
thousands)(unaudited)
For the Nine Months
Cash Flows from Ended September 30,
Operating Activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 205,653 $ 188,487
Adjustments to
reconcile net income
to
net cash provided
by operating
activities:
Depreciation and 51,260 48,511
amortization
Stock option expense 24,285 24,374
Noncash long-term 6,784 3,057
incentive compensation
Legal settlements 6,000 1,850
Noncash directors' 1,191 1,123
compensation
Benefit for deferred -456 -16,259
income taxes
Amortization of debt 255 241
issuance costs
Changes in operating
assets and
liabilities, excluding
amounts acquired in
business
combinations:
Increase in accounts -71,304 -44,403
receivable
Increase in -205 -45
inventories
Increase in prepaid -11,528 -8,603
expenses
Increase in accounts
payable and
other current 27,783 10,102
liabilities
Change in current -7,685 -2,162
income taxes
Net change in lease
assets and -667 -576
liabilities
(Increase)/decrease in -9,356 42,048
other assets
Increase in other 6,772 6,355
liabilities
Other sources 840 639
Net cash provided by
operating 229,622 254,739
activities
Cash Flows from
Investing Activities
Business combinations,
net of cash -96,050 -225
acquired
Capital expenditures -51,355 -46,447
Proceeds from sale of 488 3,751
fixed assets
Other uses -502 -468
Net cash used by -147,419 -43,389
investing activities
Cash Flows from
Financing Activities
Proceeds from
revolving line of 843,280 -
credit
Payments on revolving -607,280 -
line of credit
Purchases of treasury -350,042 -256,944
stock
Proceeds from exercise 30,281 27,152
of stock options
Dividends paid -25,234 -23,196
Change in cash 6,818 610
overdrafts payable
Capital stock
surrendered to pay
taxes -3,832 -8,484
on stock-based
compensation
Debt issuance costs -1,349 -
Other (uses)/sources -933 914
Net cash used by -108,291 -259,948
financing activities
Decrease in Cash and -26,088 -48,598
Cash Equivalents
Cash and cash
equivalents at 74,515 178,350
beginning
of year
Cash and cash
equivalents at end of $ 48,427 $ 129,752
period
CHEM…
CORP…
AND
SUBS…
COMP…
CONS…
STAT…
OF
INCO…
FOR
THE
THREE
MONT…
ENDED
SEPT…
30,
2026
AND
2025
(in
thou…
2026 Chemed
(a) VITAS Roto-… Corpo… Conso…
──────────────────────────────────────────────────────────────────────────────
Serv…
reve… $ 457,4… $ 233,5… $ - $ 690,9…
and
sales
Cost
of
serv…
prov… 341,9… 115,9… - 457,9…
and
goods
sold
Sell…
gene…
and 23,100 71,033 17,336 111,4…
admi…
expe…
Depr… 5,791 8,624 12 14,427
Amor… 25 2,949 - 2,974
Other
oper… 7,352 88 230 7,670
expe…
Total
costs 378,2… 198,6… 17,578 594,5…
and
expe…
Inco…
from 79,142 34,858 -17,5… 96,422
oper…
Inte… -54 -145 -1,898 -2,097
expe…
Inte…
inte… 6,766 4,574 -11,3… -
inco…
Other 124 5 2,254 2,383
inco…
Inco…
befo… 85,978 39,292 -28,5… 96,708
inco…
taxes
Inco… -20,2… -9,152 4,362 -25,0…
taxes
Net $ 65,708 $ 30,140 $ -24,2… $ 71,648
inco…
2025
(b)
Serv…
reve… $ 407,7… $ 217,1… $ - $ 624,9…
and
sales
Cost
of
serv…
prov… 318,0… 107,1… - 425,1…
and
goods
sold
Sell…
gene…
and 25,236 60,672 19,867 105,7…
admi…
expe…
Depr… 5,354 8,298 12 13,664
Amor… 26 2,544 - 2,570
Other
oper… 3,036 -38 - 2,998
expe…
Total
costs 351,6… 178,6… 19,879 550,1…
and
expe…
Inco…
from 56,074 38,555 -19,8… 74,750
oper…
Inte… -56 -132 -269 -457
expe…
Inte…
inte… 5,685 4,030 -9,715 -
inco…
Other 61 25 9,165 9,251
inco…
Inco…
befo… 61,764 42,478 -20,6… 83,544
inco…
taxes
Inco… -14,9… -10,4… 6,093 -19,3…
taxes
Net $ 46,771 $ 32,071 $ -14,6… $ 64,237
inco…
The
"Foo…
to
Fina…
Stat…
are
inte…
parts
of
this
fina…
info…
CHEM…
CORP…
AND
SUBS…
COMP…
CONS…
STAT…
OF
INCO…
FOR
THE
NINE
MONT…
ENDED
SEPT…
30,
2026
AND
2025
(in
thou…
2026 Chemed
(a) VITAS Roto-… Corpo… Conso…
──────────────────────────────────────────────────────────────────────────────
Serv…
reve… $ 1,320… $ 700,9… $ - $ 2,021…
and
sales
Cost
of
serv…
prov… 1,005… 346,3… - 1,351…
and
goods
sold
Sell…
gene…
and 75,314 206,3… 59,344 340,9…
admi…
expe…
Depr… 17,484 25,477 36 42,997
Amor… 78 8,185 - 8,263
Other
oper… 7,432 78 230 7,740
expe…
Total
costs 1,105… 586,4… 59,610 1,751…
and
expe…
Inco…
from 215,3… 114,5… -59,6… 270,2…
oper…
Inte… -158 -466 -3,774 -4,398
expe…
Inte…
inte… 19,484 13,661 -33,1… -
inco…
Other 285 31 10,755 11,071
inco…
Inco…
befo… 234,9… 127,7… -85,7… 276,8…
inco…
taxes
Inco… -56,0… -29,8… 14,763 -71,2…
taxes
Net $ 178,8… $ 97,837 $ -71,0… $ 205,6…
inco…
2025
(b)
Serv…
reve… $ 1,211… $ 679,3… $ - $ 1,890…
and
sales
Cost
of
serv…
prov… 951,4… 338,3… - 1,289…
and
goods
sold
Sell…
gene…
and 76,861 183,8… 50,968 311,6…
admi…
expe…
Depr… 15,863 24,899 36 40,798
Amor… 78 7,635 - 7,713
Other
oper… 3,155 -80 - 3,075
expe…
Total
costs 1,047… 554,6… 51,004 1,653…
and
expe…
Inco…
from 163,9… 124,6… -51,0… 237,5…
oper…
Inte… -150 -394 -685 -1,229
expe…
Inte…
inte… 16,436 11,930 -28,3… -
inco…
Other 170 58 13,742 13,970
inco…
Inco…
befo… 180,3… 136,2… -66,3… 250,3…
inco…
taxes
Inco… -45,3… -32,3… 15,851 -61,8…
taxes
Net $ 135,0… $ 103,9… $ -50,4… $ 188,4…
inco…
The
"Foo…
to
Fina…
Stat…
are
inte…
parts
of
this
fina…
info…
CHEM…
CORP…
AND
SUBS…
COMP…
CONS…
SUMM…
OF
EBIT…
FOR
THREE
MONT…
ENDED
SEPT…
30,
2026
AND
2025
(in
thou…
Chemed
VITAS Roto-… Corpo… Conso…
2026
Net $ 65,708 $ 30,140 $ -24,2… $ 71,648
inco…
Add/…
Inte… 54 145 1,898 2,097
expe…
Inco… 20,270 9,152 -4,362 25,060
taxes
Depr… 5,791 8,624 12 14,427
Amor… 25 2,949 - 2,974
EBIT… 91,848 51,010 -26,6… 116,2…
Add/…
Inte…
inte… -6,766 -4,574 11,340 -
expe…
Inte… -113 -5 -177 -295
inco…
Legal 6,705 - 308 7,013
sett…
Stock
opti… - - 5,984 5,984
expe…
Long…
ince… - - 3,151 3,151
comp…
Acqu… - 1,726 - 1,726
expe…
Adju… $ 91,674 $ 48,157 $ -6,046 $ 133,7…
EBIT…
2025
Net $ 46,771 $ 32,071 $ -14,6… $ 64,237
inco…
Add/…
Inte… 56 132 269 457
expe…
Inco… 14,993 10,407 -6,093 19,307
taxes
Depr… 5,354 8,298 12 13,664
Amor… 26 2,544 - 2,570
EBIT… 67,200 53,452 -20,4… 100,2…
Add/…
Inte…
inte… -5,685 -4,030 9,715 -
expe…
Inte… -69 -25 -2,462 -2,556
inco…
Stock
opti… - - 6,067 6,067
expe…
Legal 2,850 - - 2,850
sett…
Long…
ince… - - -216 -216
comp…
Other - - 2,665 2,665
Adju… $ 64,296 $ 49,397 $ -4,648 $ 109,0…
EBIT…
The
"Foo…
to
Fina…
Stat…
are
inte…
parts
of
this
fina…
info…
CHEM…
CORP…
AND
SUBS…
COMP…
CONS…
SUMM…
OF
EBIT…
FOR
THE
NINE
MONT…
ENDED
SEPT…
30,
2026
AND
2025
(in
thou…
Chemed
VITAS Roto-… Corpo… Conso…
2026
Net $ 178,8… $ 97,837 $ -71,0… $ 205,6…
inco…
Add/…
Inte… 158 466 3,774 4,398
expe…
Inco… 56,088 29,899 -14,7… 71,224
taxes
Depr… 17,484 25,477 36 42,997
Amor… 78 8,185 - 8,263
EBIT… 252,6… 161,8… -81,9… 332,5…
Add/…
Inte…
inte… -19,4… -13,6… 33,145 -
expe…
Inte… -274 -31 -1,094 -1,399
inco…
Stock
opti… - - 24,285 24,285
expe…
Legal 7,253 - 308 7,561
sett…
Long…
ince… - - 6,904 6,904
comp…
Acqu… 8 1,953 - 1,961
expe…
Adju… $ 240,1… $ 150,1… $ -18,4… $ 371,8…
EBIT…
2025
Net $ 135,0… $ 103,9… $ -50,4… $ 188,4…
inco…
Add/…
Inte… 150 394 685 1,229
expe…
Inco… 45,353 32,344 -15,8… 61,846
taxes
Depr… 15,863 24,899 36 40,798
Amor… 78 7,635 - 7,713
EBIT… 196,4… 169,2… -65,5… 300,0…
Add/…
Inte…
inte… -16,4… -11,9… 28,366 -
expe…
Inte… -176 -58 -6,952 -7,186
inco…
Stock
opti… - - 24,374 24,374
expe…
Long…
ince… - - 3,294 3,294
comp…
Legal 2,850 - - 2,850
sett…
Other - - 2,665 2,665
Adju… $ 182,7… $ 157,2… $ -13,8… $ 326,0…
EBIT…
The
"Foo…
to
Fina…
Stat…
are
inte…
parts
of
this
fina…
info…
CHEM…
CORP…
AND
SUBS…
COMP…
RECO…
OF
ADJU…
NET
INCO…
(in
thou…
exce…
per
share
data…
Net
inco…
as
repo…
Add/…
pre-…
cost
of:
Stock
opti…
expe…
Legal
sett…
Amor…
of
reac…
fran…
righ…
Long…
ince…
comp…
Acqu…
expe…
Other
Add/…
tax
impa…
Tax
impa…
of
the
above
pre-…
adju…
(1)
Exce…
tax
expe…
on
stock
comp…
Adju… 71,648 64,237 205,653 188,4…
net 5,984 6,067 24,285 24,374
inco… 7,013 2,850 7,561 2,850
2,352 2,352 7,056 7,056
Dilu… Three 3,151 (216) Nine 6,904 3,294
Earn… Months 1,726 - Months 1,961 -
Per Ended - 2,665 Ended - 2,665
Share Septem… (3,67… (2,049) Septe… (8,296) (6,51…
As 30, 521 - 30, 1,022 (513)
Repo… 2026 88,725 2025 75,906 2026 246,146 2025 221,7…
──────────────────────────────────────────────────────────────────────────────
Net $ 5.45 $ 4.46 $ 15.43 $ 12.89
inco…
Aver…
numb…
of 13,135 14,409 13,329 14,620
shar…
outs…
Adju…
Dilu…
Earn…
Per
Share
Adju…
net $ 6.75 $ 5.27 $ 18.47 $ 15.16
inco…
Aver…
numb…
of 13,135 14,409 13,329 14,620
shar…
outs…
(1)
The
tax
impa…
of
pre-…
adju…
was
calc…
using
the
effe…
tax
rate
of
the
oper…
unit
for
which
each
adju…
is
asso…
The
"Foo…
to
Fina…
Stat…
are
inte…
parts
of
this
fina…
info…
CHEM…
CORP…
AND
SUBS…
COMP…
OPER…
STAT…
FOR
VITAS
SEGM…
(una… For
the
OPER… Three Nine
STAT… Mont… Months
Net Ended Ended
reve… Sept… Septe…
($00… 30, 30,
(c) 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Home… $ 405,9… $ 362,… $ 1,16… $ 1,072…
Inpa… 36,407 33,0… 108,… 100,1…
Cont… 21,159 19,9… 58,6… 68,222
care
Other 6,421 5,807 18,2… 16,898
Subt… $ 469,9… $ 421,… $ 1,35… $ 1,257…
Room
and -3,982 -3,8… -11,… -11,2…
boar…
net
Cont… -7,743 -3,5… -17,… -9,875
allo…
Medi…
cap -828 -6,0… -3,7… -24,7…
allo…
Net $ 457,4… $ 407,… $ 1,32… $ 1,211…
Reve…
Net
reve…
as a
perc…
of
total
befo…
Medi…
cap
allo…
Home… 86.4 % 86.0 % 86.3 % 85.3 %
Inpa… 7.7 7.9 8.0 8.0
Cont… 4.5 4.7 4.3 5.4
care
Other 1.4 1.4 1.4 1.3
Subt… 100.0 100.0 100.0 100.0
Room
and -0.8 -0.8 -0.8 -0.9
boar…
net
Cont… -1.7 -0.8 -1.3 -0.8
allo…
Medi…
cap -0.2 -1.4 -0.3 -2.0
allo…
Net 97.3 % 97.0 % 97.6 % 96.3 %
Reve…
Days
of
care
Home… 1,872… 1,68… 5,35… 4,980…
Nurs… 312,6… 309,… 910,… 923,4…
home
Resp… 12,502 12,1… 35,6… 33,619
Subt…
rout…
home… 2,197… 2,00… 6,30… 5,937…
and
resp…
Inpa… 30,494 28,5… 90,6… 86,447
Cont… 19,683 18,3… 55,0… 62,576
care
Total 2,247… 2,05… 6,44… 6,086…
Numb…
of
days
in 92 92 273 273
rele…
time
peri…
Aver…
daily
cens…
("AD…
(day…
Home… 20,348 18,3… 19,6… 18,245
Nurs… 3,399 3,361 3,335 3,383
home
Resp… 136 132 131 123
Subt…
rout…
home… 23,883 21,8… 23,0… 21,751
and
resp…
Inpa… 331 310 332 317
Cont… 214 199 202 229
care
Total 24,428 22,3… 23,6… 22,297
Total 18,995 17,7… 57,5… 53,398
Admi…
Total 18,426 17,3… 55,1… 52,931
Disc…
Aver…
leng…
of 103.5 109.7 102.5 121.9
stay
(day…
Medi…
leng…
of 17.0 18.0 16.0 18.0
stay
(day…
ADC
by
major
diag…
Cere… 44.1 % 44.1 % 44.4 % 44.6 %
Neur… 11.2 11.6 11.1 11.8
Canc… 9.2 10.1 9.4 9.8
Card… 16.8 15.9 16.6 16.0
Resp… 8.1 7.7 7.9 7.4
Other 10.6 10.6 10.6 10.4
Total 100.0 % 100.0 % 100.0 % 100.0 %
Admi…
by
major
diag…
Cere… 28.0 % 27.1 % 27.5 % 27.6 %
Neur… 6.7 6.9 6.9 6.8
Canc… 24.7 26.6 24.3 25.9
Card… 14.9 14.3 15.3 14.7
Resp… 12.3 10.5 12.2 10.9
Other 13.4 14.6 13.8 14.1
Total 100.0 % 100.0 % 100.0 % 100.0 %
Esti…
unco…
acco…
as a 1.2 % 0.9 % 1.3 % 0.8 %
perc…
of
reve…
Acco…
rece…
--
Days
of
reve…
outs… 39.0 37.5 n.a. n.a.
unap…
Medi…
paym…
Days
of
reve…
outs… 37.4 34.0 n.a. n.a.
unap…
Medi…
paym…
CHE…
COR…
AND
SUB…
COM…
FOO… Incl…
TO in
FIN… the
STA… resu…
FOR of
THE oper…
THR… for
AND 2026
NINE are
MON… the
END… foll…
SEP… sign…
30, cred…
2026 which
AND may
2025 not
(un… be Three
indi… Mont…
(a) of Ended
ongo… Sept…
oper… 30,
(in 2026
thou… VITAS Roto… Corp… Conso…
──────────────────────────────────────────────────────────────────────────────
Legal $ -6,7… $ - $ -308 $ -7,0…
sett…
Stock
opti… - - -5,9… -5,9…
expe…
Long…
ince… - - -3,1… -3,1…
comp…
Amor…
of
reac… - -2,3… - -2,3…
fran…
agre…
Acqu… - -1,7… - -1,7…
expe…
Pret…
impa… -6,7… -4,0… -9,4… -20,…
on
earn…
Exce…
tax
expe… - - -521 -521
on
stock
comp…
Inco…
tax
bene… 1,629 950 1,091 3,670
on
the
above
Afte…
impa… $ -5,0… $ -3,1… $ -8,8… $ -17,…
on
earn…
Nine
Mont…
Ended
Sept…
30,
2026
VITAS Roto… Corp… Conso…
Stock
opti… $ - $ - $ -24,… $ -24,…
expe…
Legal -7,2… - -308 -7,5…
sett…
Amor…
of
reac… - -7,0… - -7,0…
fran…
agre…
Long…
ince… - - -6,9… -6,9…
comp…
Acqu… -8 -1,9… - -1,9…
expe…
Pret…
impa… -7,2… -9,0… -31,… -47,…
on
earn…
Exce…
tax
expe… - - -1,0… -1,0…
on
stock
comp…
Inco…
tax
bene… 1,764 2,100 4,432 8,296
on
the
above
Afte…
impa… $ -5,4… $ -6,9… $ -28,… $ -40,…
on
earn…
Incl…
in
the
resu…
of
oper…
for
2025
are
the
(b) foll…
sign…
cred…
which
may
not
be
indi…
of
ongo…
oper…
(in
thou…
Three
Mont…
Ended
Sept…
30,
2025
VITAS Roto… Corp… Conso…
Stock
opti… $ - $ - $ -6,0… $ -6,0…
expe…
Legal -2,8… - - -2,8…
sett…
Amor…
of
reac… - -2,3… - -2,3…
fran…
agre…
Long…
ince… - - 216 216
comp…
Other - - -2,6… -2,6…
Pret…
impa… -2,8… -2,3… -8,5… -13,…
on
earn…
Inco…
tax
bene… 698 546 805 2,049
on
the
above
Afte…
impa… $ -2,1… $ -1,8… $ -7,7… $ -11,…
on
earn…
Nine
Mont…
Ended
Sept…
30,
2025
VITAS Roto… Corp… Conso…
Stock
opti… $ - $ - $ -24,… $ -24,…
expe…
Amor…
of
reac… - -7,0… - -7,0…
fran…
agre…
Long…
ince… - - -3,2… -3,2…
comp…
Legal -2,8… - - -2,8…
sett…
Other - - -2,6… -2,6…
Pret…
impa… -2,8… -7,0… -30,… -40,…
on
earn…
Exce…
tax
bene… - - 513 513
on
stock
comp…
Inco…
tax
bene… 698 1,637 4,177 6,512
on
the
above
Afte…
impa… $ -2,1… $ -5,4… $ -25,… $ -33,…
on
earn…
VITAS has 14 large (greater than 450 ADC), 25 medium (greater than 200
but less than 450 ADC) and 21 small (less than 200 ADC) hospice
(c) programs. Of Vitas' 33 Medicare provider numbers, for the current cap
year, 21 provider numbers have a Medicare cap cushion of greater than
10%, seven provider numbers have a Medicare cap cushion between 0% and
10%, and five provider numbers have a Medicare cap liability.